Should a multiparametric prostate MRI include a dynamic contrast‑enhanced (DCE) sequence?

Should Multiparametric Prostate MRI Include Contrast?

The answer depends critically on the clinical context: for post-focal therapy surveillance, contrast (DCE) is mandatory and cannot be omitted; for initial prostate cancer detection and diagnosis, biparametric MRI (without contrast) is generally sufficient and should be the standard approach.

Post-Focal Therapy Setting: Contrast is MANDATORY

A multiparametric protocol that includes T2W, DWI, and DCE sequences is required for patients who have undergone focal therapy 1. In this specific setting:

• DCE is the most important sequence for detecting recurrence 1
• Biparametric protocols that omit DCE images cannot be used 1
• DCE serves as the major sequence in the TARGET scoring system (scored out of 3), while DWI and T2W are joint minor sequences 1
• The ability to discriminate between suspicious and normal tissue on DCE images is actually better after focal therapy than in treatment-naïve glands 1

Technical Specifications for Post-Focal Therapy

• Temporal resolution: 10-15 seconds (7 seconds is not preferable) 1
• Slice thickness: 2-3 mm (panel uncertain on preference) 1
• If DCE sequence is missing or inadequate on post-treatment MRI, it must be repeated 1

Initial Detection/Diagnosis Setting: Contrast is OPTIONAL

For treatment-naïve patients undergoing prostate cancer detection, the evidence strongly supports biparametric MRI (bpMRI) as the standard:

Why Biparametric MRI Should Be Standard 2

Biparametric MRI (T2W + DWI without DCE) exhibits similar detection rates for clinically significant prostate cancer while offering several advantages:

• Safer (no gadolinium contrast reactions)
• Less expensive
• Reduces environmental gadolinium emissions
• Faster acquisition time

Evidence on Diagnostic Performance

The 2017 ACR Appropriateness Criteria acknowledges that "the incremental benefit of perfusion imaging on tumor detection is relatively modest" and that "the administration of intravenous gadolinium will likely confer only slightly improved tumor evaluation over the same study performed without contrast" 3.

However, there is nuance in the research evidence:

Supporting biparametric MRI:

• Meta-analysis of 45 studies (5,217 patients) showed pooled specificity was nearly identical: bpMRI 0.81 vs mpMRI 0.82 (P=0.169) 4
• One study found no statistical difference in detection of clinically significant cancer between exams with and without contrast 5

Favoring multiparametric MRI:

• The same meta-analysis showed sensitivity was significantly lower for bpMRI: 0.77 vs mpMRI 0.84 (P=0.001) 4
• Visual grading analysis demonstrated significantly better lesion visibility with mpMRI (AUCVGC 0.62, p<0.001) 6
• DCE contributed to marked diagnostic yield in 83% of patients, particularly for detecting contralateral peripheral zone tumors and extraprostatic extension 7
• Recent 2025 study showed combined T2WI+DWI had AUC 0.902, but adding DCE improved overall diagnostic accuracy 8

Reader Experience Matters

Less experienced readers (<500 prostate MRIs) missed 20.8% of clinically significant cancers with mpMRI and 22.6% with bpMRI, while expert readers (>5,000 MRIs) missed only 1.9% with mpMRI and 11.3% with bpMRI 9. This suggests:

• Expert readers can work effectively with bpMRI
• Less experienced readers benefit more from DCE sequences
• Overall accuracy improved significantly with DCE for less experienced readers (79.8% vs 66.9%, p=0.017) 9

Clinical Algorithm for Deciding

Use Multiparametric MRI WITH Contrast When:

1. Post-focal therapy surveillance (mandatory) 1
2. Negative bpMRI with persistent clinical suspicion of prostate cancer 2
3. Radiological challenges (e.g., hip replacement affecting DWI quality) 2
4. Less experienced readers performing the interpretation 9
5. Staging evaluation where extraprostatic extension assessment is critical 7

Use Biparametric MRI WITHOUT Contrast When:

1. Initial prostate cancer detection/screening in treatment-naïve patients 2
2. Expert readers available (>5,000 prostate MRI experience) 9
3. Patient factors favor avoiding gadolinium (renal impairment, contrast allergy history)

Common Pitfalls to Avoid

• Never use biparametric MRI for post-focal therapy surveillance – this is explicitly contraindicated 1
• Don't assume negative MRI excludes cancer – even mpMRI has imperfect sensitivity 10
• Don't rely solely on DCE – it should complement, not replace, T2W and DWI evaluation 11
• Consider institutional expertise – centers with less experienced readers should maintain DCE sequences 9

The final results from the prospective, multicenter PRIME study (bpMRI vs mpMRI before biopsy) are still pending and will provide definitive guidance for the detection setting 2.